Additional beneficiary effects are that only a pre-selected cohort of clinical samples has to be analysed by the specialized laboratories and that those patients that are negative for EHC but positive for pathogens like Campylobacter spec. or Clostridium difficile can be administered the correct antibiotic therapy.